Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.

@article{Amory2004ExogenousTO,
  title={Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.},
  author={J. Amory and N. Watts and Kirk A Easley and P. R. Sutton and B. Anawalt and A. Matsumoto and W. Bremner and J. Tenover},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2004},
  volume={89 2},
  pages={
          503-10
        }
}
Older men, particularly those with low serum testosterone (T) levels, might benefit from T therapy to improve bone mineral density (BMD) and reduce fracture risk. Concerns exist, however, about the impact of T therapy on the prostate in older men. We hypothesized that the combination of T and finasteride (F), a 5 alpha-reductase inhibitor, might increase BMD in older men without adverse effects on the prostate. Seventy men aged 65 yr or older, with a serum T less than 12.1 nmol/liter on two… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of… Expand
ConditionsHealthy Males, Male Contraceptive
InterventionDrug, Other
Interventional Clinical Trial
The purposes of this study are: - to determine the role of testosterone versus dihydrotestosterone with respect to the following physiological functions: bone… Expand
ConditionsTranssexualism
InterventionDrug
Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone.
TLDR
The results indicate that T replacement, whether given alone or in combination with finasteride, for 36 months in healthy older men without cognitive impairment at baseline has no clinically significant effect on tests of cognitive function. Expand
Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome
TLDR
Testosterone treatment in men with TDS has a good safety profile, leads to significant improvement in lumbar spine and hip BMD, and improves symptoms, as assessed by the AMS questionnaire. Expand
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.
TLDR
In older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD, and does not improve skeletal health in aging men with low or low normal testosterone levels. Expand
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
TLDR
It is demonstrated that T therapy in older men with low serum T improves physical performance and strength over 36 months, when administered alone or when combined with F, and suggested that high serum levels of dihydrotestosterone are not essential for these beneficial effects of T in men. Expand
Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial
TLDR
Testosterone treatment for 1 year of older men with low testosterone significantly increased volumetric BMD and estimated bone strength, more in trabecular than peripheral bone and more in the spine than hip. Expand
Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized‐controlled trial
TLDR
This proof‐of‐concept study confirms that aromatization of T is required for maintaining BMD in older men with low‐T levels and uncovers the novel finding that aromats need to be placed in combination with T for improvement in fast gait speed. Expand
Comparison of Testosterone, Alendronate, and a Combination of Both Therapies in Men with Low Bone Mineral Density
TLDR
The results suggest that the combination of testosterone and alendronate does not appear to be superior to single-drug therapy in men with low bone mass in the authors' patient population. Expand
Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men
TLDR
Testosterone therapy elicited a positive effect only in lumbar BMD in elderly men with diminished testosterone serum levels, whereas no significant change occurred in femoral neck BMD. Expand
Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.
TLDR
It is concluded that a higher-than-replacement TE combined with finasteride significantly increases muscle strength and BMD and reduces body fat without causing prostate enlargement. Expand
Andropause or male menopause? Rationale for testosterone replacement therapy in older men with low testosterone levels.
  • G. Cunningham
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2013
TLDR
The Testosterone Trial should provide definitive information regarding the potential benefits of TRT in men ≥65 years of age and if efficacy is confirmed, there will still need more information about the risks ofTRT in older men. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Effect of testosterone treatment on bone mineral density in men over 65 years of age.
TLDR
Increasing the serum testosterone concentrations of normal men over 65 yr of age to the midnormal range for young men did not increase lumbar spine bone density overall, but did increase it in those men with low pretreatment serumosterone concentrations. Expand
Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.
TLDR
Transdermal testosterone (5 mg/d) prevented bone loss at the femoral neck, decreased body fat, and increased lean body mass in a group of healthy men over age 65 with low bioavailable testosterone levels, and demonstrated gains in lower extremity muscle strength. Expand
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
TLDR
In hypogonadal men, BMD can be normalized and maintained in the normal range by continuous, long term testosterone substitution, and is seen during the first year of treatment in previously untreated patients with low initial BMD. Expand
Differential effects of androgens and estrogens on bone turnover in normal men.
TLDR
The data suggest that both androgens and estrogens play independent and fundamental roles in regulating bone resorption in men and suggest that androgens may play an important role in the regulation of bone formation in men. Expand
Effects of testosterone replacement in hypogonadal men.
TLDR
It is concluded from this study that replacing testosterone in hypogonadal men increases bone mineral density of the spine and hip, fat-free mass, prostate volume, erythropoiesis, energy, and sexual function. Expand
Alendronate for the treatment of osteoporosis in men.
TLDR
In men with osteoporosis, alendronate significantly increases spine, hip, and total-body bone mineral density and helps prevent vertebral fractures and decreases in height. Expand
Determinants of bone density in healthy older men with low testosterone levels.
TLDR
The results suggest the need for testosterone replacement and physical activity intervention trials in men at risk for osteoporotic fractures. Expand
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.
TLDR
It is shown that age-related bone loss may be the result of E deficiency not just in postmenopausal women, but also in men, and bioavailable E levels decline significantly with age and are important predictors of BMD in men as well as women. Expand
Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.
TLDR
The data indicate that estrogen plays a key role both in the acquisition of peak bone mass in young men and in bone loss in elderly men, and suggest that age-related decreases in bioavailable estradiol levels to below 40 pmol/liter may well be the major cause of bone lossIn elderly men. Expand
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
TLDR
It is concluded that testosterone therapy given to adult men with acquired hypogonadism decreases sc fat and increases lean muscle mass and testosterone therapy reduces bone remodeling and increases trabecular bone density. Expand
...
1
2
3
4
5
...